Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Willie Earley, MD
Allergan
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
88 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Forest Investigative Site 311
Kardzhali, Bulgaria
- Forest Investigative Site 307
Kazanlak, Bulgaria
- Forest Investigative Site 310
Lovech, Bulgaria
- Forest Investigative Site 313
Novi Iskar, Bulgaria
- Forest Investigative Site 309
Pazardzhik, Bulgaria
- Forest Investigative Site 302
Pleven, Bulgaria
- Forest Investigative Site 301
Plovdiv, Bulgaria
- Forest Investigative Site 305
Sofia, Bulgaria
- Forest Investigative Site 306
Sofia, Bulgaria
- Forest Investigative Site 308
Tsarev Brod, Bulgaria
- Forest Investigative Site 312
Tserova Koria, Bulgaria
- Forest Investigative Site 102
Kelowna, British Columbia, Canada
- Forest Investigative Site 103
Penticton, British Columbia, Canada
- Forest Investigative Site 101
Chatham, Ontario, Canada
- Forest Investigative Site 804
Barranquilla, Colombia
- Forest Investigative Site 806
Barranquilla, Colombia
- Forest Investigative Site 803
Bogotá, Colombia
- Forest Investigative Site 805
Bogotá, Colombia
- Forest Investigative Site 808
Bogotá, Colombia
- Forest Investigative Site 807
Pereira, Colombia
- Forest Investigative Site 601
Arkhangelsk, Russia
- Forest Investigative Site 605
Moscow, Russia
- Forest Investigative Site 607
Moscow, Russia
- Forest Investigative Site 611
Moscow, Russia
- Forest Investigative Site 619
Moscow, Russia
- Forest Investigative Site 603
Nizhny Novgorod, Russia
- Forest Investigative Site 602
Saint Petersburg, Russia
- Forest Investigative Site 604
Saint Petersburg, Russia
- Forest Investigative Site 606
Saint Petersburg, Russia
- Forest Investigative Site 608
Saint Petersburg, Russia
- Forest Investigative Site 612
Saint Petersburg, Russia
- Forest Investigative Site 613
Saint Petersburg, Russia
- Forest Investigative Site 615
Saint Petersburg, Russia
- Forest Investigative Site 617
Samara, Russia
- Forest Investigative Site 616
Saratov, Russia
- Forest Investigative Site 609
Tomsk, Russia
- Forest Investigative Site 618
Tver', Russia
- Forest Investigative Site 610
Voronezh, Russia
- Forest Investigative Site 707
Kerch, AR Crimea, Ukraine
- Forest Investigative Site 709
Kherson, Vil. Stepanivka, Ukraine
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jul 2011
- Primary completion
- 10 Jan 2014
- Completion
- 10 Jan 2014
- Last update posted
- 1 May 2018
- Registered enrollment
- 584
- Registry id
- NCT01396447
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.